Adma Biologics (ADMA) Current Leases (2011 - 2026)
Adma Biologics' (ADMA) quarterly Current Leases came in at $1.1 million in Q4 2025, down 10.02% YoY from $1.2 million in Q4 2024, and down 15.56% on a QoQ basis from $1.3 million in Q3 2025.
Adma Biologics (ADMA) Current Leases (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Current Leases data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Current Leases fell 10.02% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 10.02% YoY) and the FY2025 annual result came in at $1.1 million, down 10.02% from the prior year.
- Current Leases declined to $1.1 million in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.3 million in Q3 2025 to a low of $317910.0 in Q1 2021.
- A 5-year average of $898699.1 and a median of $981213.5 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases jumped 105.72% — and 2025, when it decreased 10.02%.
- Tracing ADMA's Current Leases over 5 years: stood at $591084.0 in 2021, then soared by 53.11% to $905000.0 in 2022, then grew by 15.47% to $1.0 million in 2023, then rose by 16.56% to $1.2 million in 2024, then retreated by 10.02% to $1.1 million in 2025.
- The last three Current Leases figures came in at $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 982,891.00 |
| Jun 30, 2023 | 979,536.00 |
| Mar 31, 2023 | 956,045.00 |
| Dec 31, 2022 | 905,000.00 |
| Sep 30, 2022 | 720,755.00 |
| Jun 30, 2022 | 579,661.00 |
| Mar 31, 2022 | 654,003.00 |
| Dec 31, 2021 | 591,084.00 |
| Sep 30, 2021 | 501,239.00 |
| Jun 30, 2021 | 385,858.00 |